Fig. 6From: hGC33-Modified and Sorafenib-Loaded Nanoparticles have a Synergistic Anti-Hepatoma Effect by Inhibiting Wnt Signaling PathwayGPC3-activated Wnt signal transduction in HCC. Fifty percent Wnt3a DMEM medium was added with anti-wnt3a antibody, hGC33, or hGC33-null-NP. HepG2 (GPC3++), Huh-7 (GPC3+) and Li-7 (GPC3−) cells were co-incubated for 48 h, and cell proliferation was measured by MTT assay. The data were expressed as mean ± SD (*P < 0.01)Back to article page